Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.
In addition, Arrowhead Pharmaceuticals, the sponsor of plozasiran, announced the top-line results of the phase 3 PALISADE trial, in which plozasiran reduced APOC3 and triglycerides for patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome, and lowered risk for acute pancreatitis in that population.
SHASTA-2 included 226

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.
In addition, Arrowhead Pharmaceuticals, the sponsor of plozasiran, announced the top-line results of the phase 3 PALISADE trial, in which plozasiran reduced APOC3 and triglycerides for patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome, and lowered risk for acute pancreatitis in that population.
SHASTA-2 included 226